Spyre Therapeutics announces pricing of upsized $403 million public offering of common stock

Market Closed – Nasdaq			5-day change	1st Jan Change
64.01 ^USD	+1.17%		+25.02%	+95.39%

Published on 04/14/2026
at 10:40 pm EDT

Reuters

10:40pm	Spyre Therapeutics announces pricing of upsized $403 million public offering of common stock	RE
Apr. 14	Mizuho Boosts Price Target on Spyre Therapeutics to $84 From $53, Keeps Outperform Rating	MT
Apr. 14	Deutsche Bank Adjusts Spyre Therapeutics PT to $88 From $55, Maintains Buy Rating	MT
Apr. 13	Spyre Therapeutics announces proposed public offering of its common stock	RE
Apr. 13	Spyre Therapeutics Inc suspends and terminates ATM prospectus for at-the-market offering effective April 13, 2026 – SEC filing	RE
Apr. 13	Spyre Therapeutics Launches $300 Million Stock Offering	MT
Apr. 13	Spyre Therapeutics, Inc. Announces Potential Best-In-Class SPY001 Induction Results From Skyline Trial In Moderate-To-Severe Ulcerative Colitis Patients	CI
Apr. 13	Top Midday Gainers	MT
Apr. 13	Wedbush Adjusts Price Target on Spyre Therapeutics to $80 From $65, Maintains Outperform Rating	MT
Apr. 13	Global markets live: Goldman Sachs, Baker Hughes, Conagra Brands, Microsoft, Lufthansa…
Apr. 13	Spyre Therapeutics, Inc. – Special Call
Apr. 13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Trump Prepares to Block Strait of Hormuz	MT
Apr. 13	Spyre Therapeutics’ SPY001 to Treat Ulcerative Colitis Meets Phase 2 Trial Endpoints; Shares Surge Pre-Bell	MT
Apr. 13	Spyre’s inflammatory bowel drug shown to reduce disease activity in mid-stage study	RE
Apr. 13	Spyre Therapeutics reports positive 12-week phase 2 data for SPY001 in Skyline trial	RE

Duration

Period

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).